Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis exec Richard Smith joins EMD Serono

He becomes senior vice president and head of US fertility and endocrinology

EMD Serono Richard SmithMerck KGaA's US biopharmaceutical business EMD Serono has appointed Richard Smith as senior vice president and head of US fertility and endocrinology.

Smith will take on responsibility for the two businesses as well as the firm's fertility technologies division, which launched its first medical device last year.

He joins EMD Serono from Novartis, where he spent the last 18 years in a series of roles across the company's commercial business, most recently as vice president and US head of sales and operations of its cardiovascular franchise.

Prior to this role, Smith served as executive director and head of Novartis' transplant franchise, as well as positions in customer segment marketing, strategy and commercial operations for specialty medicines, brand managed markets strategy, and pricing and contracting for its neuroscience franchise.

Gary Zieziula, president and managing director of EMD Serono, said: “We have a longstanding focus on providing comprehensive solutions in the areas of fertility and endocrinology care through innovative products as well as financial, educational and emotional support.

“Adding Richard's expertise, passion and industry knowledge to our strong and committed team will ensure that we are well-positioned to further meet the needs of patients and customers.”

25th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics